An artificial pancreas system combines an insulin pump, continuous glucose monitor (CGM), and software that allows the two devices to communicate and automatically manage blood glucose without any input from the wearer. Some current systems do that partially, but not completely. One barrier is that insulin deposited under the skin takes time to begin working, so glucose levels can still spike. To overcome that, researchers added a drug called pramlintide (Symlin), typically used in people with type 2 diabetes, to slow food absorption and give insulin more time to work. Among 28 people with type 1 diabetes, adding pramlintide to insulin in the system increased the amount of time spent in target blood glucose range from 74 percent with insulin alone to 84 percent. This study was done in the hospital, so the next step would be a real-world study.
Source: Diabetes Care, published online Feb. 27, 2020